Baxter International has announced that Baxter BioPharma Solutions has entered into an agreement to provide...
Baxter’s BioPharma Solutions facility in Bloomington, Indiana, was recognised for the fifth time as the Best Contract Manufacturing Organization at the annual Vaccine Industry Excellence (ViE) Awards, held during the 2017 World Vaccine Congress in Washington, DC.
The awards recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry over the previous 12 months.
Committed to a customer service philosophy to provide service with a passionate focus on results and continuous improvement, Baxter BioPharma Solutions was a previous recipient of the ViE Award in 2010, 2011, 2012 and 2015.
The criteria to be recognised as Best Contract Manufacturing Organization include a range of services provided in niche and core therapeutic areas, methods of performance improvement or introduction of new services, attention to and quality of relationships with clients, milestones reached and final or on-going outcomes, as well as building and maintaining of existing and long-term partnerships.
Vice-president of BioPharma Solutions said Marie Keeley said: “Baxter BioPharma Solutions is honoured to be recognised by the World Vaccine Congress and the vaccine industry as the best in class.”
Plant manager for Baxter’s Bloomington facility Susan Easton further commented: “Being selected as the Best Contract Manufacturing Organization for the fifth time in eight years demonstrates our commitment to continuous process and customer service improvement to better serve customers and patients worldwide.”
The BioPharma Solutions facility in Bloomington manufactures critical, life-saving products for pharmaceutical and biotechnology companies, and provides a variety of services, including clinical development through commercial launch, formulation, and packaging.
The Bloomington facility also has expertise in clinical and commercial vaccines, which include pandemic, preventative and seasonal vaccines for global markets.
Processes and systems at Baxter’s BioPharma Solutions facility in Bloomington include high-speed contract manufacturing and automated inspection systems. These are tailored to meet clients’ parenteral manufacturing needs.
With its sister contract manufacturing facility in Halle (Westfalen), BioPharma Solutions works with a majority of the top 20 pharmaceutical companies and currently provides sterile contract manufacturing services to more than 60 clients. The business has been a leader in parenteral contract manufacturing for more than 35 years, offering services for aseptic bags, prefilled syringes, liquid and lyophilised vials and cartridge filling, as well as specialised capabilities for cytotoxics and biologics manufacturing.
The Halle expansion includes the installation of a new commercial filling line with two freeze dryers, as well as a clinical filling line with an additional freeze dryer. Both the new commercial and clinical lines are equipped with automated loading / unloading, capping and inspection infrastructure, designed to support international manufacturing and regulatory requirements.
The Halle facility completed an approximately 2,000m2 fill / finish contract manufacturing capacity expansion in 2015. The facility has continued to expand to meet clients’ growing needs for cytotoxic manufacturing, and the most recent expansion further enhanced Halle’s complete range of resources to support early phase drug formulation through commercial scale-up, product launch and lifecycle management.
Baxter Biopharma Solutions Announces $50m Investment for Bloomington Sterile Fill/Finish Manufacturing Site
Global leader in sterile medication production and delivery, Baxter International, is pleased to announce a...
Baxter International Inc representatives globally are rising to the call and making a difference in...
The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers...